Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Clinical trial NCT06911255 · RECRUITING

Trial details

NCT number: NCT06911255
Sponsor: Yoon Jun Kim
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Unresectable Hepatocellular Carcinoma

Start date: 2025-04-18
Primary completion: 2028-03-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.